explore -WSS

explore

author：comprehensive 2025-09-30 08:49:41 - browse：2858

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Medicare bonuses could stop drug shortages under Senate plan

focus

leisure time

WSS

Brain technologies pose threats that are all too real, experts warn

FDA sets aggressive timeline for overhauling inspection procedures

Dana Farber says 6 studies to be retracted and 31 corrected

AI for drug discovery: Experts on separating hype from reality

Flu vaccine reformulation won't be easy, manufacturers warn

As health system earnings go up, health insurance stocks go down

hotspot

explore

Gilead needs Arcellx more than ever

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Flu vaccine reformulation won't be easy, manufacturers warn

Medicare proposal to cover medical devices draws a mixed reaction

Medicare drug price lawsuits could be good politics for Biden

Guidelines to prevent youth baseball injuries need more muscle

CVS is on a mission to consolidate health care. Will it work?

Hollywood unions extend contract negotiations for actors

A pediatrician calls for Congress to pass the child tax credit deal

Hepatitis C has a cure — but many Americans still lack access to it

Future doctors need a strong humanities education

leisure time

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Microsoft launches AI tool for clinical documentation through Epic

AltruBio raises $225 million to develop ulcerative colitis drug

Deliver public health messages at the right time

Novel spinal cord stimulator treats paralysis without surgery

Is it ever OK for doctors to lie to their patients?

focus

leisure time

explore

focus